Notably, we established ACC1 malonylation as a clinically actionable target for lipid metabolism-driven malignancies, offering a mechanistic foundation for novel combinatorial regimens targeting the malonylation-autophagy axis to overcome therapeutic resistance in cholangiocarcinoma. This evidence concerns the gene ACACA and cholangiocarcinoma.